Effect of M&A announcement on acquirer stock prices in the Pharmaceutical sector and the role of bid premium

Abstract: A majority of previous studies reveal evidences of negative or no abnormal returns for the bidder/acquirer firm upon the announcement of a merger or acquisition (M&A). Additionally, these studies stress on the importance of ‘bid premium’ announced as a key factor influencing acquirer returns post M&A announcement. This paper aims to find validity for the above-mentioned statements in case of a ‘Pharmaceutical sector setting’ because not many previous studies have analyzed the role of bid premium influencing abnormal stock returns for the acquirer/bidder firm in M&A’s taking place in the pharmaceutical sector. We applied ‘event study methodology’ to study the abnormal returns’ and our results suggest positive returns to M&A announcements around the world for the period from 1997-2015. Furthermore, we carried out an OLS regression to observe the influence of ‘bid premium’ (announced at the time of M&A announcement), on the abnormal stock returns. We control for acquirer firm characteristics by adding them as control variables in the analysis. Our findings suggest that bid premium negatively affects the acquirer abnormal returns around the time of the M&A announcement.